Author: Editor

Melissa L. Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute speaks about Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study.Link to Article:https://www.jto.org/article/S1556-0864(21)02067-0/fulltextAbstract:Introduction:DLL3, an unusual Notch ligand expressed in SCLC tumors, is targeted by Rovalpituzumab tesirine (Rova-T), an antibody-drug combination. After platinum-based chemotherapy, we compared the effectiveness of Rova-T vs placebo as a maintenance treatment in patients with advanced-stage–SCLC.Methods:MERU was a randomized, double-blind, placebo-controlled trial in its third phase. Patients who had not progressed following four rounds of platinum-based front-line treatment were given 0.3 mg/kg…

Melissa L. Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute speaks about Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study.Link to Article:https://www.jto.org/article/S1556-0864(21)02067-0/fulltextAbstract:Introduction:DLL3, an unusual Notch ligand expressed in SCLC tumors, is targeted by Rovalpituzumab tesirine (Rova-T), an antibody-drug combination. After platinum-based chemotherapy, we compared the effectiveness of Rova-T vs placebo as a maintenance treatment in patients with advanced-stage–SCLC.Methods:MERU was a randomized, double-blind, placebo-controlled trial in its third phase. Patients who had not progressed following four rounds of platinum-based front-line treatment were given 0.3 mg/kg…

Andrew J. Armstrong, MD, Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute speaks about the ESMO 2021 Abstract – LBA25 – Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/final-overall-survival-os-analysis-from-arches-a-phase-iii-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-anAbstract LBA25Background:ENZA + ADT, compared to PBO + ADT, decreased the risk of radiographic progression and improved secondary outcomes in males with mHSPC in the ARCHES (NCT02677896) study. The final OS (after 356 events), a significant secondary objective in ARCHES and an important benchmark…

Andrew J. Armstrong, MD, Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute speaks about the ESMO 2021 Abstract – LBA25 – Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/final-overall-survival-os-analysis-from-arches-a-phase-iii-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-anAbstract LBA25Background:ENZA + ADT, compared to PBO + ADT, decreased the risk of radiographic progression and improved secondary outcomes in males with mHSPC in the ARCHES (NCT02677896) study. The final OS (after 356 events), a significant secondary objective in ARCHES and an important benchmark…

Joleen M. Hubbard, MD, Oncology Department, Mayo Clinic speaks about the ESMO 2021 Abstract – 507TiP – PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer.   Link to Abstract: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/preserve-1-a-phase-iii-randomized-double-blind-trial-of-trilaciclib-versus-placebo-in-patients-receiving-folfoxiri-bevacizumab-for-metastatic-co 507TiP Abstract:Background:Based on results from three randomized, placebo-controlled phase II studies, the FDA has authorized trilaciclib, an intravenous (IV) kinase inhibitor that preserves hematopoeitic stem and progenitor cells following chemotherapy exposure. In another randomized phase II study, giving trilaciclib before chemotherapy had modest myeloprotective effects but increased overall survival in patients with triple-negative breast cancer (OS).Design of the…

Joleen M. Hubbard, MD, Oncology Department, Mayo Clinic speaks about the ESMO 2021 Abstract – 507TiP – PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/preserve-1-a-phase-iii-randomized-double-blind-trial-of-trilaciclib-versus-placebo-in-patients-receiving-folfoxiri-bevacizumab-for-metastatic-co507TiP Abstract:Background:Based on results from three randomized, placebo-controlled phase II studies, the FDA has authorized trilaciclib, an intravenous (IV) kinase inhibitor that preserves hematopoeitic stem and progenitor cells following chemotherapy exposure. In another randomized phase II study, giving trilaciclib before chemotherapy had modest myeloprotective effects but increased overall survival in patients with triple-negative breast cancer (OS).Design of the experiment:PRESERVE 1 (NCT04607668) is…

Ignace B. Vergote, MD, Ph.D., Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven speaks about ESMO 2021 Abstract – 723MO – Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/tisotumab-vedotin-tv-carboplatin-carbo-in-first-line-1l-or-pembrolizumab-pembro-in-previously-treated-2l-3l-recurrent-or-metastatic-cAbstract 723MOBackground:In previously treated r/mCC, TV exhibited persistent activity (objective response rate [ORR]=24 percent; median duration of response [mDOR]=8.3 mo) with manageable safety (Lancet Oncol. 2021; 22:609-619). The results of the 2-part, multi-cohort phase Ib/II study ENGOT-cx8/GOG-3024/innovaTV 205 in r/mCC…

Ignace B. Vergote, MD, Ph.D., Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven speaks about ESMO 2021 Abstract – 723MO – Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/tisotumab-vedotin-tv-carboplatin-carbo-in-first-line-1l-or-pembrolizumab-pembro-in-previously-treated-2l-3l-recurrent-or-metastatic-cAbstract 723MOBackground:In previously treated r/mCC, TV exhibited persistent activity (objective response rate [ORR]=24 percent; median duration of response [mDOR]=8.3 mo) with manageable safety (Lancet Oncol. 2021; 22:609-619). The results of the 2-part, multi-cohort phase Ib/II study ENGOT-cx8/GOG-3024/innovaTV 205 in r/mCC…

Merle Ronden, MD Department of Radiation Oncology, VU University Medical Center speaks about The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.Link to Abstract:https://www.jtocrr.org/article/S2666-3643(21)00054-0/fulltextOverview:Intro:Treatment for stage III NSCLC varies a lot from country to country. Adjuvant durvalumab following concurrent chemoradiotherapy improved progression-free and overall survival in the PACIFIC study (CCRT). Between 2015 and 2019, we looked at treatment decisions made by three Dutch regional thoracic multidisciplinary tumor boards to see if there were any changes in practice when adjuvant durvalumab became accessible.Methodologies:Patients with stage III NSCLC had their information obtained…

Merle Ronden, MD Department of Radiation Oncology, VU University Medical Center speaks about The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.Link to Abstract:https://www.jtocrr.org/article/S2666-3643(21)00054-0/fulltextOverview:Intro:Treatment for stage III NSCLC varies a lot from country to country. Adjuvant durvalumab following concurrent chemoradiotherapy improved progression-free and overall survival in the PACIFIC study (CCRT). Between 2015 and 2019, we looked at treatment decisions made by three Dutch regional thoracic multidisciplinary tumor boards to see if there were any changes in practice when adjuvant durvalumab became accessible.Methodologies:Patients with stage III NSCLC had their information obtained…

Dr. Aaron Goodman of UCSD speaks with hosts Jack West and Charu Aggarwal explaining the remarkable level of engagement he achieves in offering medical education on hematology via Twitter, especially his wildly successful polls.

Marshall R. Posner, MD, Director of Head and Neck Medical Oncology at The Tisch Cancer Institute at Mount Sinai speaks about the ESMO 2021 Abstract – 961MO – Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/safety-efficacy-immunogenicity-of-arenavirus-based-vectors-hb-201-and-hb-202-in-patients-with-hpv16-cancers961MO Abstract:Background:HPV16+ malignancies are generated by the persistent expression of HPV16-specific E7 and E6 oncoproteins, which are also sources of immunogenic neoantigens. The replicating arenavirus vectors HB-201 (LCMV) and HB-202 (Pichinde viral) elicit tumor-specific T-cell responses by producing the identical non-oncogenic HPV16 E7E6 fusion protein.Methods:In HPV16+ malignancies, a phase I first-in-human research looked at HB-201 monotherapy and…

Marshall R. Posner, MD, Director of Head and Neck Medical Oncology at The Tisch Cancer Institute at Mount Sinai speaks about the ESMO 2021 Abstract – 961MO – Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/safety-efficacy-immunogenicity-of-arenavirus-based-vectors-hb-201-and-hb-202-in-patients-with-hpv16-cancers961MO Abstract:Background:HPV16+ malignancies are generated by the persistent expression of HPV16-specific E7 and E6 oncoproteins, which are also sources of immunogenic neoantigens. The replicating arenavirus vectors HB-201 (LCMV) and HB-202 (Pichinde viral) elicit tumor-specific T-cell responses by producing the identical non-oncogenic HPV16 E7E6 fusion protein.Methods:In HPV16+ malignancies, a phase I first-in-human research looked at HB-201 monotherapy and…

Professor Sanjay Popat, Consultant Medical Oncologist BSc MBBS FRCP Ph.D., The Royal Marsden NHS Foundation Trust speaks about the ESMO 2021 Abstract – 1195P – Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L.Link to Abstract:https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=ALTA&r=pt%7E53Abstract:Background:BRG BIRC-assessed PFS was superior to CRZ in two planned interim assessments of ALTA-1L (NCT02737501). The ALTA-1L results are presented in their final form.Methods:ALK TKI–naive advanced ALK+ NSCLC patients (pts) were enrolled and categorized by baseline (BL), brain metastases (BM), and previous treatment (CT). A previous CT scan for advanced NSCLC and asymptomatic BM was permitted. BRG 180 mg qd…

Professor Sanjay Popat, Consultant Medical Oncologist BSc MBBS FRCP Ph.D., The Royal Marsden NHS Foundation Trust speaks about the ESMO 2021 Abstract – 1195P – Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L.Link to Abstract:https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=ALTA&r=pt%7E53Abstract:Background:BRG BIRC-assessed PFS was superior to CRZ in two planned interim assessments of ALTA-1L (NCT02737501). The ALTA-1L results are presented in their final form.Methods:ALK TKI–naive advanced ALK+ NSCLC patients (pts) were enrolled and categorized by baseline (BL), brain metastases (BM), and previous treatment (CT). A previous CT scan for advanced NSCLC and asymptomatic BM was permitted. BRG 180 mg qd…

Saura Manich from the Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron speaks about ESMO 2021 Abstract – LBA15 – Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/primary-outcome-of-the-phase-iii-syd985.002-tulip-trial-comparing-vic-trastuzumab-duocarmazine-to-physician-s-choice-treatment-in-patients-with-pLBA15 Abstract:Background:[vic-]Trastuzumab duocarmazine (SYD985, Byondis B.V., NL) is a new HER2-targeting antibody–drug combination made up of trastuzumab linked to a duocarmycin-containing linker molecule. TULIP looked at SYD985’s effectiveness in advanced HER2-positive breast cancer.Methods:The TULIP study (NCT03262935) randomly allocated HER2-positive locally advanced or metastatic breast cancer (MBC)…

Saura Manich from the Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron speaks about ESMO 2021 Abstract – LBA15 – Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/primary-outcome-of-the-phase-iii-syd985.002-tulip-trial-comparing-vic-trastuzumab-duocarmazine-to-physician-s-choice-treatment-in-patients-with-pLBA15 Abstract:Background:[vic-]Trastuzumab duocarmazine (SYD985, Byondis B.V., NL) is a new HER2-targeting antibody–drug combination made up of trastuzumab linked to a duocarmycin-containing linker molecule. TULIP looked at SYD985’s effectiveness in advanced HER2-positive breast cancer.Methods:The TULIP study (NCT03262935) randomly allocated HER2-positive locally advanced or metastatic breast cancer (MBC)…

Kevin Punie, MD Medical Oncologist Specialized in treatment of TNBC from the University Hospitals Leuven, Belgium speaks about ESMO 2021 Abstract – 257P – Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).Link to Abstract:https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=257PAbstract:Origins:The anti–Trop-2 antibody is linked to SN-38 by a unique hydrolyzable linker in SG, which is an antibody-drug conjugate. In the ASCENT intention-to-treat study, SG substantially improved progression-free survival (PFS; median 4.8 vs 1.7 mo) and overall survival (OS; median 11.8 vs 6.9 mo) in the second line or larger (2L+) mTNBC scenario compared to single-agent…

ASCENT Trial and Trodelvy (Sacituzumab Govitecan) Improves Progression Free Survival in Metastatic Triple Negative Breast (mTNBC) 5 Key Stats for Trodelvy (Sacituzumab Govitecan) from the ASCENT Trial Trodelvy significantly prolonged progression-free survival (median PFS; 4.8 vs 1.7 mo)  Overall survival (median OS; 11.8 vs 6.9 mo) vs single-agent chemotherapy of physician’s choice (TPC) in the second line or greater (2L+) mTNBC setting. Patients (Pts) with mTNBC who received ≥2 prior systemic therapies (at least 1 for metastatic disease) were randomized to receive Sacituzumab Govitecan (10 mg/kg IV on d 1 and 8, every 21 d) or TPC (capecitabine, eribulin, vinorelbine, or…

Professor Sergei Krasny, MD, DSc, deputy director of the N.N. Alexandrov National Cancer Centre of Belarus and Alexander Shneider, Ph.D., Founder and CEO, CureLab Oncology, Inc. speaks about Hormone-resistant Prostate And Breast Cancers Added To Clinical Study Based On Encouraging Preliminary Results.Link to Article:https://www.eurekalert.org/news-releases/924187The Ministry of Health of the Republic of Belarus has approved extending CureLab Oncology’s ElenagenTM, an investigational DNA treatment, clinical study to include two new arms: 1) hormone-resistant breast cancer and 2) hormone-resistant metastatic prostate cancer. Elenagen was included in the current research because of promising early findings in triple-negative breast cancer and platinum-resistant ovarian cancer patients…

Professor Sergei Krasny, MD, DSc, deputy director of the N.N. Alexandrov National Cancer Centre of Belarus and Alexander Shneider, Ph.D., Founder and CEO, CureLab Oncology, Inc. speaks about Hormone-resistant Prostate And Breast Cancers Added To Clinical Study Based On Encouraging Preliminary Results.Link to Article:https://www.eurekalert.org/news-releases/924187The Ministry of Health of the Republic of Belarus has approved extending CureLab Oncology’s ElenagenTM, an investigational DNA treatment, clinical study to include two new arms: 1) hormone-resistant breast cancer and 2) hormone-resistant metastatic prostate cancer. Elenagen was included in the current research because of promising early findings in triple-negative breast cancer and platinum-resistant ovarian cancer patients…

Mark LaBarge, Ph.D., professor in City of Hope’s Department of Population Sciences, and Sundus Shalabi, Ph.D. candidate at the City of Hope speak about Evidence For Accelerated Aging In Mammary Epithelia Of Women Carrying Germline BRCA1 Or BRCA2 Mutations.Link to Abstract:https://www.nature.com/articles/s43587-021-00104-9 Abstract:Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age, exhibiting markers typically found in myoepithelial cells. We believe that loss of lineage fidelity is a common symptom of epithelia that is predisposed to cancer start. We show in this work that histologically normal breast tissue from younger women who are vulnerable to breast cancer…

Mark LaBarge, Ph.D., professor in City of Hope’s Department of Population Sciences, and Sundus Shalabi, Ph.D. candidate at the City of Hope speak about Evidence For Accelerated Aging In Mammary Epithelia Of Women Carrying Germline BRCA1 Or BRCA2 Mutations.Link to Abstract:https://www.nature.com/articles/s43587-021-00104-9 Abstract:Luminal epithelial cells in the human mammary gland lose lineage fidelity as they age, exhibiting markers typically found in myoepithelial cells. We believe that loss of lineage fidelity is a common symptom of epithelia that is predisposed to cancer start. We show in this work that histologically normal breast tissue from younger women who are vulnerable to breast cancer…

Mauro Di Pilato, Ph.D., Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Department of Immunology, The University of Texas MD Anderson Cancer Center speaks about CXCR6 Positions Cytotoxic T cells To Receive Critical Survival Signals In The Tumor Microenvironment.Link to Article:https://www.cell.com/cell/fulltext/S0092-8674(21)00856-4#%20Emphasizes:• CXCR6 is required for long-term tumor suppression by CD8+ cytotoxic T cells (CTLs)• CXCR6 improves CTL interactions with typical DCs in the CCR7+ DC3 state.• To survive in the TME, DC3s trans-present IL-15 to TCF-1neg effector-like CTLs.• DC3s are densely clustered in the tumor stroma’s T cell-rich perivascular niches.Overview:CTL responses against malignancies are…

Mauro Di Pilato, Ph.D., Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Department of Immunology, The University of Texas MD Anderson Cancer Center speaks about CXCR6 Positions Cytotoxic T cells To Receive Critical Survival Signals In The Tumor Microenvironment.Link to Article:https://www.cell.com/cell/fulltext/S0092-8674(21)00856-4#%20Emphasizes:• CXCR6 is required for long-term tumor suppression by CD8+ cytotoxic T cells (CTLs)• CXCR6 improves CTL interactions with typical DCs in the CCR7+ DC3 state.• To survive in the TME, DC3s trans-present IL-15 to TCF-1neg effector-like CTLs.• DC3s are densely clustered in the tumor stroma’s T cell-rich perivascular niches.Overview:CTL responses against malignancies are…

Vince Miller, MD is one of the world’s experts in lung cancer and clinical trial design and interpretation. His work was critical to identification of EGFR sensitizing and resistance mutations, Physician-in-Chief at EQRx speaks about the ESMO 2021 Abstract – Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer.Link to Article:https://www.eqrx.com/press-release/aumolertinib-significantly-prolongs-progression-free-survival-with-fewer-side-effects-in-the-first-line-treatment-of-advanced-egfr-mutated-non-small-cell-lung-cancer/Background: Au is a potent, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that specifically suppresses both EGFR sensitizing and resistance mutations. In China, Au has been authorized for the treatment of patients with EGFR…

Vince Miller, MD is one of the world’s experts in lung cancer and clinical trial design and interpretation. His work was critical to identification of EGFR sensitizing and resistance mutations, Physician-in-Chief at EQRx speaks about the ESMO 2021 Abstract – Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer.Link to Article:https://www.eqrx.com/press-release/aumolertinib-significantly-prolongs-progression-free-survival-with-fewer-side-effects-in-the-first-line-treatment-of-advanced-egfr-mutated-non-small-cell-lung-cancer/Background: Au is a potent, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that specifically suppresses both EGFR sensitizing and resistance mutations. In China, Au has been authorized for the treatment of patients with EGFR…

Vince Miller, MD is one of the world’s experts in lung cancer and clinical trial design and interpretation. His work was critical to identification of EGFR sensitizing and resistance mutations, Physician-in-Chief at EQRx speaks about the ESMO 2021 Abstract – LBA43 – GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/gemstone-301-a-randomized-double-blind-placebo-controlled-phase-iii-study-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cellBackground:The standard of treatment for patients (pts) with unresectable stage III NSCLC is concurrent CRT (cCRT) followed by immunotherapy. However, because almost half of this group…

Vince Miller, MD is one of the world’s experts in lung cancer and clinical trial design and interpretation. His work was critical to identification of EGFR sensitizing and resistance mutations, Physician-in-Chief at EQRx speaks about the ESMO 2021 Abstract – LBA43 – GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/gemstone-301-a-randomized-double-blind-placebo-controlled-phase-iii-study-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cellBackground:The standard of treatment for patients (pts) with unresectable stage III NSCLC is concurrent CRT (cCRT) followed by immunotherapy. However, because almost half of this group…

Mark Pegram, MD the Susy Yuan-Huey Hung Professor, Medicine – Oncology, Stanford Hospital, and Clinics speaks about ESMO 2021 Abstract LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study (Enhertu).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/trastuzumab-deruxtecan-t-dxd-vs-trastuzumab-emtansine-t-dm1-in-patients-pts-with-her2-metastatic-breast-cancer-mbc-results-of-the-randomiLBA1 Abstract  -Background:Based on the outcomes of DESTINY-Breast01, T-DXd is a HER2-targeting antibody–drug conjugate that has been authorized for patients with advanced HER2+ mBC (NCT03248492). DESTINY-Breast03 (NCT03529110) is a multicenter, open-label, randomized phase 3 trial evaluating the effectiveness and safety of T-DXd against T-DM1 in patients with HER2+ mBC who had previously…

Mark Pegram, MD the Susy Yuan-Huey Hung Professor, Medicine – Oncology, Stanford Hospital, and Clinics speaks about ESMO 2021 Abstract LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study (Enhertu).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/trastuzumab-deruxtecan-t-dxd-vs-trastuzumab-emtansine-t-dm1-in-patients-pts-with-her2-metastatic-breast-cancer-mbc-results-of-the-randomiLBA1 Abstract  -Background:Based on the outcomes of DESTINY-Breast01, T-DXd is a HER2-targeting antibody–drug conjugate that has been authorized for patients with advanced HER2+ mBC (NCT03248492). DESTINY-Breast03 (NCT03529110) is a multicenter, open-label, randomized phase 3 trial evaluating the effectiveness and safety of T-DXd against T-DM1 in patients with HER2+ mBC who had previously…

Hope S. Rugo, MD, Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education, UCSF Helen Dillard Family Comprehensive Cancer Center speaks about ESMO 2021 Abstract – #LBA16, Proffered Paper: Final Results of KEYNOTE-355: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/keynote-355-final-results-from-a-randomized-double-blind-phase-iii-study-of-first-line-pembrolizumab-chemotherapy-vs-placebo-chemotherapy-forLBA16 Abstract:Background:In a previous interim analysis of KEYNOTE-355 (NCT02819518), patients (pts) with metastatic TNBC whose tumors expressed PD-L1 (CPS 10) saw a substantial improvement in PFS compared to placebo (pbo) + chemo (HR, 0.65, 95 percent…

Hope S. Rugo, MD, Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education, UCSF Helen Dillard Family Comprehensive Cancer Center speaks about ESMO 2021 Abstract – #LBA16, Proffered Paper: Final Results of KEYNOTE-355: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/keynote-355-final-results-from-a-randomized-double-blind-phase-iii-study-of-first-line-pembrolizumab-chemotherapy-vs-placebo-chemotherapy-forLBA16 Abstract:Background:In a previous interim analysis of KEYNOTE-355 (NCT02819518), patients (pts) with metastatic TNBC whose tumors expressed PD-L1 (CPS 10) saw a substantial improvement in PFS compared to placebo (pbo) + chemo (HR, 0.65, 95 percent…

Bradley Monk, MD, FACOG, FACS, Gynecologic Oncologist, Arizona Oncology speaks about the ESMO 2021 Abstract #LBA2, Presidential Symposium: KEYNOTE-826: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019/keynote-826-a-phase-iii-randomized-study-of-chemotherapy-with-or-without-pembrolizumab-for-first-line-treatment-of-persistent-recurrent-or-metas265TiP Abstract:Background:Patients with advanced cervical cancer have a significant chance of death and a poor prognosis. Although adding the anti-VEGF agent bevacizumab to platinum- and taxane-based chemotherapy (CT) is associated with a modest OS benefit compared to CT alone (median OS, 16.8 vs 13.3 mo; hazard ratio, 0.77, 95 percent CI, 0.62-0.95; P = 0.007; Tewari…

Bradley Monk, MD, FACOG, FACS, Gynecologic Oncologist, Arizona Oncology speaks about the ESMO 2021 Abstract #LBA2, Presidential Symposium: KEYNOTE-826: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019/keynote-826-a-phase-iii-randomized-study-of-chemotherapy-with-or-without-pembrolizumab-for-first-line-treatment-of-persistent-recurrent-or-metas265TiP Abstract:Background:Patients with advanced cervical cancer have a significant chance of death and a poor prognosis. Although adding the anti-VEGF agent bevacizumab to platinum- and taxane-based chemotherapy (CT) is associated with a modest OS benefit compared to CT alone (median OS, 16.8 vs 13.3 mo; hazard ratio, 0.77, 95 percent CI, 0.62-0.95; P = 0.007; Tewari…

Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.Link to Article:https://pubmed.ncbi.nlm.nih.gov/34321279/Summary -The discovery of new medicines has changed the therapeutic paradigm for multiple myeloma (MM), with MRD negative now possible throughout the whole disease spectrum. Real-time clinical tools for the sensitive identification and monitoring of MRD in MM patients have been given by bone marrow-based technologies to measure MRD, including methods employing next-generation flow and next-generation sequencing. Complementary liquid biopsy-based assays are rapidly evolving, with some, such as mass spectrometry techniques, nearing clinical…

Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.Link to Article:https://pubmed.ncbi.nlm.nih.gov/34321279/Summary -The discovery of new medicines has changed the therapeutic paradigm for multiple myeloma (MM), with MRD negative now possible throughout the whole disease spectrum. Real-time clinical tools for the sensitive identification and monitoring of MRD in MM patients have been given by bone marrow-based technologies to measure MRD, including methods employing next-generation flow and next-generation sequencing. Complementary liquid biopsy-based assays are rapidly evolving, with some, such as mass spectrometry techniques, nearing clinical…

Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about MMRF CureCloud – First At-home Genomic Testing Program/Multiple Myeloma.Link to MMRF CureCloud:https://mmrfcurecloud.org/In the first at-home genetic testing program, the MMRF CureCloud will integrate huge quantities of health data from thousands of multiple myeloma patients. It is the world’s first, largest, and most comprehensive myeloma database. It is also an important resource for scientists, clinicians, and patients who are striving to create cures, enhance patient quality of life, and identify therapies.Myeloma is not only an uncommon illness, but it also has a wide range of symptoms. Our groundbreaking…

Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about MMRF CureCloud – First At-home Genomic Testing Program/Multiple Myeloma.Link to MMRF CureCloud:https://mmrfcurecloud.org/In the first at-home genetic testing program, the MMRF CureCloud will integrate huge quantities of health data from thousands of multiple myeloma patients. It is the world’s first, largest, and most comprehensive myeloma database. It is also an important resource for scientists, clinicians, and patients who are striving to create cures, enhance patient quality of life, and identify therapies.Myeloma is not only an uncommon illness, but it also has a wide range of symptoms. Our groundbreaking…

Jason J. Luke, MD, FACP, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center speaks about ESMO 2021 Abstract #LBA3, Presidential Symposium: Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage II Melanoma: Efficacy and Safety Results From the KEYNOTE-716 Double-Blind Phase III Trial. Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/pembrolizumab-versus-placebo-after-complete-resection-of-high-risk-stage-ii-melanoma-efficacy-and-safety-results-from-the-keynote-716-double-blindLBA3_PR Abstract -Background:Observation is the current standard of treatment for patients (pts) after excision of high-risk stage II melanoma. We compared pembrolizumab (pembro) to placebo in patients with resected AJCC-8 stage IIB or IIC melanoma in phase 3 double-blind KEYNOTE-716 study. The first interim study of recurrence-free survival (RFS) is presented.Methods:Patients over the age of 12…

Jason J. Luke, MD, FACP, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center speaks about ESMO 2021 Abstract #LBA3, Presidential Symposium: Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage II Melanoma: Efficacy and Safety Results From the KEYNOTE-716 Double-Blind Phase III Trial. Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/pembrolizumab-versus-placebo-after-complete-resection-of-high-risk-stage-ii-melanoma-efficacy-and-safety-results-from-the-keynote-716-double-blindLBA3_PR Abstract -Background:Observation is the current standard of treatment for patients (pts) after excision of high-risk stage II melanoma. We compared pembrolizumab (pembro) to placebo in patients with resected AJCC-8 stage IIB or IIC melanoma in phase 3 double-blind KEYNOTE-716 study. The first interim study of recurrence-free survival (RFS) is presented.Methods:Patients over the age of 12…

David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about the ESMO 2021 Abstract – LBA34 – Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-agent-anti-pd-1-balstilimab-or-in-combination-with-anti-ctla-4-zalifrelimab-for-recurrent-metastatic-r-m-cervical-cancer-cc-preliminaryBackground:The lack of second-line therapy for R/M CC remains a significant therapeutic need. In R/M CC, data from two phase 2 trials of balstilimab (bal) alone and in conjunction with zalifrelimab (zal) are presented.Methods:Patients received bal…

David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about the ESMO 2021 Abstract – LBA34 – Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/single-agent-anti-pd-1-balstilimab-or-in-combination-with-anti-ctla-4-zalifrelimab-for-recurrent-metastatic-r-m-cervical-cancer-cc-preliminaryBackground:The lack of second-line therapy for R/M CC remains a significant therapeutic need. In R/M CC, data from two phase 2 trials of balstilimab (bal) alone and in conjunction with zalifrelimab (zal) are presented.Methods:Patients received bal…

David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about the Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.Link to Abstract:https://www.gynecologiconcology-online.net/article/S0090-8258(21)01316-0/fulltextSummary -Objective:Balstilimab, an anti-PD-1 antibody, was tested in patients with previously treated, recurrent/metastatic cervical cancer for its safety and anticancer efficacy in this phase II clinical study.Methods:Patients who had recurrent and/or metastatic cervical cancer and had relapsed following a previous platinum-based therapy regimen for advanced disease were eligible. Balstilimab was given intravenously once every two weeks at…

David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about the Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.Link to Abstract:https://www.gynecologiconcology-online.net/article/S0090-8258(21)01316-0/fulltextSummary -Objective:Balstilimab, an anti-PD-1 antibody, was tested in patients with previously treated, recurrent/metastatic cervical cancer for its safety and anticancer efficacy in this phase II clinical study.Methods:Patients who had recurrent and/or metastatic cervical cancer and had relapsed following a previous platinum-based therapy regimen for advanced disease were eligible. Balstilimab was given intravenously once every two weeks at…

David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about ESMO 2021 Abstract – 724MO – Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/balstilimab-anti-pd-1-in-combination-with-zalifrelimab-anti-ctla-4-final-results-from-a-phase-ii-study-in-patients-pts-with-recurrent-metastBackground:The treatment of R/M CC in the second line remains a serious clinical issue. Multiple cancers have been successfully treated by blocking both the PD-1 and CTLA-4 immune checkpoints. We present the results of a large single-arm…

David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James speaks about ESMO 2021 Abstract – 724MO – Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC).Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/balstilimab-anti-pd-1-in-combination-with-zalifrelimab-anti-ctla-4-final-results-from-a-phase-ii-study-in-patients-pts-with-recurrent-metastBackground:The treatment of R/M CC in the second line remains a serious clinical issue. Multiple cancers have been successfully treated by blocking both the PD-1 and CTLA-4 immune checkpoints. We present the results of a large single-arm…

June-Wha Rhee, MD, cardiologist with specialized clinical and research training in cardiovascular drug toxicity and pharmacogenomics, from Stanford Hospital and Clinics speaks about Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications.Link to Abstract:https://www.ahajournals.org/doi/pdf/10.1161/HCG.0000000000000082Overview:The main causes of mortality in the United States are cardiovascular disease and cancer, with hormone-dependent tumors (breast and prostate cancer) being the most frequent noncutaneous malignancies in women and men, respectively. The hormonal (endocrine-related) treatments that are used to treat both malignancies enhance survival rates, but they significantly raise cardiovascular morbidity and death in survivors. This…

June-Wha Rhee, MD, cardiologist with specialized clinical and research training in cardiovascular drug toxicity and pharmacogenomics, from Stanford Hospital and Clinics speaks about Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications.Link to Abstract:https://www.ahajournals.org/doi/pdf/10.1161/HCG.0000000000000082Overview:The main causes of mortality in the United States are cardiovascular disease and cancer, with hormone-dependent tumors (breast and prostate cancer) being the most frequent noncutaneous malignancies in women and men, respectively. The hormonal (endocrine-related) treatments that are used to treat both malignancies enhance survival rates, but they significantly raise cardiovascular morbidity and death in survivors. This…

Dr. Shikha Jain of the University of Illinois & Chair of the Women in Medicine Summit joins Charu Aggarwal & Jack West to discuss sexism & harassment, as well as education & medical practice options for women (and men) after the COVID-19 pandemic.